Clinical trials: Psoriasis Patients
Psoriatic Arthritis, Spondyloarthritis, Axial
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
- Trial name
- UP-SPOUT (NCT06454188)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- 5 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- CARE ARTHRITIS LTD.
Psoriasis
Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the…
- Trial name
- NCT00581165
- Testing
- Etanercept
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Psoriatic
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.
- Trial name
- NCT01009086
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 615 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis, Moderate to Severe
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
- Trial name
- NCT00162253
- Testing
- BMS 587101
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients
This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose…
- Trial name
- NCT02555709
- Testing
- VTP-43742
- Where
- 14 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Arthritis, Psoriatic
Single Dose PG102 in Patients With Active Psoriatic Arthritis
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis.
- Trial name
- NCT00787137
- Testing
- PG102
- Where
- Serbia
- Volunteers
- 17 people
- Sponsor
- PanGenetics UK Limited
Generalized Pustular Psoriasis
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP).
- Trial name
- NCT05239039
- Testing
- spesolimab
- Where
- 12 sites in China
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts.
- Trial name
- NCT06808815
- Testing
- DC-806
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Plaque Psoriasis
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of…
- Trial name
- NCT06380907
- Testing
- ZL-1102 1% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel QD for 16 weeks
- Where
- 10 sites in Australia
- Volunteers
- 65 people
- Sponsor
- Zai Lab (Hong Kong), Ltd.
Tuberculosis
A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
This was a retrospective observational study that relied on data extracted from patient's chart review at the participating centers.
- Trial name
- ToBeReal (NCT06715254)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Plaque
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
The purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.
- Trial name
- NCT02274363
- Testing
- No Intervention
- Where
- 16 sites in Brazil
- Volunteers
- 1,131 people
- Sponsor
- Janssen Pharmaceutica
Psoriasis
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years.
- Trial name
- NCT01169987
- Volunteers
- 191 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis, Rheumatoid Arthritis
BE Study in Patients - Methotrexate Tablets
To characterize the pharmacokinetic profile of the Test product - Methotrexate Tablets USP, 2.5 mg of Amneal Pharmaceuticals, compared to that of the corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufactured…
- Trial name
- NCT02940561
- Testing
- Methotrexate - Amneal, Methotrexate - DAVA
- Where
- 3 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Skin and Connective Tissue Diseases
A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
The purpose of this study is to evaluate the anti-psoriatic effect of LP0113 aerosol spray compared to Daivobet® gel, LEO 90100 aerosol foam, betamethasone dipropionate in the aerosol spray vehicle, calcipotriol in the aerosol…
- Trial name
- LP0113-1123 (NCT02416258)
- Testing
- LP0113 aerosol spray, Aerosol spray vehicle, LEO 90100 aerosol foam
- Where
- France
- Volunteers
- 50 people
- Sponsor
- LEO Pharma
Psoriasis, Ulcerative Colitis
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Phase 1 study in 2 stages with 2 expansion cohorts. The first stage is a single ascending dose (SAD) study of APVO210 in healthy volunteers.
- Trial name
- NCT03768219
- Testing
- APVO210
- Where
- Australia
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Aptevo Therapeutics
Psoriasis
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in…
- Trial name
- NCT07256015
- Testing
- Deucravacitinib
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
This protocol describes randomized, multicenter, blinded (subjects), 16-week, controlled study in parallel balanced groups of psoriasis (Ps) patients to evaluate the impact of Mind.Px on response to biologic treatments.
- Trial name
- MATCH (NCT05036889)
- Testing
- Mind.Px Report
- Volunteers
- 200 people
- Sponsor
- Mindera Health